Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM-ET 2.0: Anagrelide Retard versus Thromboreductin in essential thrombocythemia
2013-003410-41Phase 3Completed
- Sponsor
- AOP Health
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of anagrelide in thrombocythemia (2 arms), sponsored by AOP Health. Primary endpoint: Mean platelet count during maintenance phase. Started Nov 2013; status: completed.
02
Drugs
anagrelide
03
Conditions
thrombocythemia
Beyond the preview
Go deeper on 2013-003410-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003410-41.